Free Trial
NASDAQ:LGND

Ligand Pharmaceuticals (LGND) Stock Price, News & Analysis

Ligand Pharmaceuticals logo
$186.66 -0.08 (-0.04%)
Closing price 04:00 PM Eastern
Extended Trading
$186.66 0.00 (0.00%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ligand Pharmaceuticals Stock (NASDAQ:LGND)

Advanced

Key Stats

Today's Range
$179.00
$187.30
50-Day Range
$151.08
$186.74
52-Week Range
$93.58
$187.76
Volume
135,408 shs
Average Volume
155,493 shs
Market Capitalization
$3.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$176.50
Consensus Rating
Moderate Buy

Company Overview

Ligand Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

LGND MarketRank™: 

Ligand Pharmaceuticals scored higher than 77% of companies evaluated by MarketBeat, and ranked 203rd out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ligand Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.

  • Downside Risk

    Ligand Pharmaceuticals has a consensus price target of $176.50, representing about 5.4% downside from its current price of $186.66.

  • Amount of Analyst Coverage

    Ligand Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Ligand Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Ligand Pharmaceuticals are expected to grow by 114.45% in the coming year, from $1.73 to $3.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ligand Pharmaceuticals is -46.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ligand Pharmaceuticals is -46.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ligand Pharmaceuticals has a P/B Ratio of 4.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Ligand Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.12% of the outstanding shares of Ligand Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Ligand Pharmaceuticals has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Ligand Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Ligand Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.12% of the outstanding shares of Ligand Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Ligand Pharmaceuticals has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Ligand Pharmaceuticals has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Ligand Pharmaceuticals has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Ligand Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    9 people have searched for LGND on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ligand Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,929,262.00 in company stock.

  • Percentage Held by Insiders

    Only 7.00% of the stock of Ligand Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    91.28% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ligand Pharmaceuticals' insider trading history.
Receive LGND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LGND Stock News Headlines

This dark force is about to change everything
An unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.tc pixel
Ligand to Host Investor Day on December 9, 2025
See More Headlines

LGND Stock Analysis - Frequently Asked Questions

Ligand Pharmaceuticals' stock was trading at $107.15 at the beginning of the year. Since then, LGND stock has increased by 74.2% and is now trading at $186.66.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its quarterly earnings data on Thursday, August, 7th. The biotechnology company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. Ligand Pharmaceuticals's quarterly revenue was up 14.7% on a year-over-year basis.
Read the conference call transcript
.

Top institutional shareholders of Ligand Pharmaceuticals include Congress Asset Management Co. (3.40%), Rice Hall James & Associates LLC (1.50%), Allspring Global Investments Holdings LLC (0.55%) and Moody Aldrich Partners LLC (0.13%). Insiders that own company stock include John L Higgins, Todd C Davis, Jason Aryeh, Matthew E Korenberg, John W Kozarich, Andrew Reardon, John L Lamattina, Stephen L Sabba, Octavio Espinoza and Nancy Ryan Gray.
View institutional ownership trends
.

Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ligand Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
8/07/2025
Today
10/21/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LGND
CIK
886163
Employees
80
Year Founded
1987

Price Target and Rating

High Price Target
$206.00
Low Price Target
$143.00
Potential Upside/Downside
-5.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
107.95
P/E Growth
N/A
Net Income
-$4.03 million
Net Margins
-40.44%
Pretax Margin
-45.04%
Return on Equity
-9.21%
Return on Assets
-8.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.45
Quick Ratio
5.21

Sales & Book Value

Annual Sales
$187.58 million
Price / Sales
19.51
Cash Flow
$1.65 per share
Price / Cash Flow
113.05
Book Value
$43.95 per share
Price / Book
4.25

Miscellaneous

Outstanding Shares
19,597,000
Free Float
18,225,000
Market Cap
$3.66 billion
Optionable
Optionable
Beta
0.95

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:LGND) was last updated on 10/21/2025 by MarketBeat.com Staff
From Our Partners